Saturday 17 October 2026
Export ACOG’s income statement to Excel — free account
Alpha Cognition Inc.
ACOG Healthcare Biotechnology
Alpha Cognition Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.2 million. In the quarter to June 2026, revenue grew 267.6%, EPS grew 38.5% and free cash flow fell 109.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
8.19
0.26
−3.08%
Follow ACOG
Alpha Cognition Inc. (ACOG) P/E ratio
Alpha Cognition Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 2 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| TRDA Entrada Therapeutics, Inc. compare | n/m |
| ELDN Eledon Pharmaceuticals, Inc. compare | n/m |
| BCYC Bicycle Therapeutics PLC Sponsored ADR compare | n/m |
| ADCT ADC Therapeutics SA compare | n/m |
| UPB Upstream Bio, Inc. compare | n/m |
| ACOG Alpha Cognition Inc. | n/m |
| SION Sionna Therapeutics, Inc. compare | n/m |
| YARW Yarrow Bioscience, Inc compare | n/m |
| STRO Sutro Biopharma, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)